866-997-4948(US-Canada Toll Free)

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 919 Pages

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2017, provides an overview of the Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline landscape.

HIV is a virus which attacks the immune system, and weakens ability to fight infections and disease. Symptoms include fever, sore throat, body rash, joint pain, muscle pain and swollen glands. The most common ways HIV is spread are by having vaginal or anal intercourse without a condom with someone who has HIV/AIDS, sharing needles or syringes with someone who has HIV/AIDS, being deeply punctured with a needle or surgical instrument contaminated with HIV and getting HIV-infected blood, semen, or vaginal secretions into open wounds or sores.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 1, 16, 46, 37, 1, 4, 114, 75 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 17, 15, 57 and 66 molecules, respectively.

Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 9
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Overview 10
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Development 11
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Assessment 53
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Companies Involved in Therapeutics Development 71
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Drug Profiles 144
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects 829
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products 858
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Product Development Milestones 862
Appendix 875

List of Tables
Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Products under Development by Companies, H1 2017 (Contd..15), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..5), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..6), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Number of Products by Stage and Molecule Type, H1 2017 (Contd..1), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AbbVie Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Abivax SA, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AdAlta Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Advanced Genetic Systems Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Akshaya Bio Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Allergan Plc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Altor BioScience Corp, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Altravax Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Amarna Therapeutics BV, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by American Gene Technologies International Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Amunix Operating Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Antigen Express Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Aphios Corp, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ApoPharma Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Argos Therapeutics Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Arno Therapeutics Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Atreca Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by B Cell Design SAS, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biological Mimetics Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biotron Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bolder Biotechnology Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bristol-Myers Squibb Company, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bukwang Pharm Co Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by C4X Discovery Holdings PLC, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Calimmune Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Camurus AB, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by CEL-SCI Corp, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Celgene Corp, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Celldex Therapeutics Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Chipscreen Biosciences Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Cocrystal Pharma Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by CompleGen Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ConjuChem LLC, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Critical Outcome Technologies Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Curevac AG, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Cytodyn Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Enzo Biochem Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by EpiVax Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by eTheRNA Immunotherapies NV, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Etubics Corp, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Excision BioTherapeutics Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by FIT Biotech Oy, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Fountain Biopharma Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Frontier Biotechnologies Co Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Galmed Pharmaceuticals Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by GeneCure LLC, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by GeoVax Labs Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Gilead Sciences Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by GlaxoSmithKline Plc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Globeimmune Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by GW Pharmaceuticals Plc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by H-Phar SA, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Heat Biologics Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by iCo Therapeutics Inc., H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ID Pharma Co Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by IGXBio Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Immune Response BioPharma Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Immune Therapeutics Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ImmunoClin Corp, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Immunocore Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Immunotope Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Immusoft Corp, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ImQuest Life Sciences Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by InnaVirVax SA, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Innovative Targeting Solutions Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Japan Tobacco Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Johnson & Johnson, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Karyopharm Therapeutics Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by KPI Therapeutics Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Kymab Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Longevity Biotech Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by MacroGenics Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Medestea Research & Production SpA, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Medivir AB, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Merck & Co Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Mologen AG, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Mycenax Biotech Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Mymetics Corp, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Myrexis Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by NanoViricides Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Navigen Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by NeED Pharma srl, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by New World Laboratories Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Novartis AG, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Omeros Corp, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Oncolys BioPharma Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Oncovir Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Orbis Biosciences Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Osel Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by OyaGen Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by PaxVax Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Peregrine Pharmaceuticals Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Pharis Biotec GmbH, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Phoenix Biotechnology Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by PlantForm Corp, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Profectus BioSciences Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Recombio SL, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Relmada Therapeutics Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Rodos BioTarget GmbH, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sangamo Therapeutics Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sanofi Pasteur SA, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sigma-Tau SpA, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Sirenas Marine Discovery LLC, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Solon Eiendom ASA, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Spider Biotech, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Spring Bank Pharmaceuticals Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Starpharma Holdings Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Susavion Biosciences Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Taiga Biotechnologies Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TaiMed Biologics Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Takara Bio Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TechnoVax Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TeneoBio Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Theratechnologies Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Theravectys SA, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Transgene Biotek Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by TVAX Biomedical Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by United Biomedical Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Vaccibody AS, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Vault Pharma Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by VG Life Sciences Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Vichem Chemie Research Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ViiV Healthcare Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Viriom Inc, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by ViroStatics srl, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by XL-protein GmbH, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..2), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..3), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..4), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..5), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..6), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..7), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..8), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..9), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..10), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..11), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..12), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..13), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..14), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..15), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..16), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..17), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..18), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..19), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..20), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..21), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..22), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..23), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..24), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2017 (Contd..25), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products, H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products, H1 2017 (Contd..1), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products, H1 2017 (Contd..2), H1 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products, H1 2017 (Contd..3), H1 2017

List of Figures
Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *